Royal Bank Of Canada reissued their outperform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) in a report published on Monday morning, StockTargetPrices.com reports. The brokerage currently has a C$46.00 price objective on the specialty pharmaceutical company’s stock.
VRX has been the topic of several other research reports. TD Securities reiterated a hold rating and set a C$38.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Thursday, July 14th. Scotiabank reduced their price target on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating on the stock in a report on Monday, July 25th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of C$38.67.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 32.01 on Monday. The firm’s 50 day moving average is $36.76 and its 200 day moving average is $35.38. The stock’s market capitalization is $11.12 billion. Valeant Pharmaceuticals Intl has a 52-week low of $24.32 and a 52-week high of $240.40.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.